What would you like to look for?
Site search
18 May 2018

Polyphor, clinical-stage biopharmaceutical company focused on the discovery and development of innovative antibiotics and other specialty pharma products for severe or life-threatening diseases, set the offer price for its shares in the initial public offering (“IPO”) at CHF 38 per share. The shares of the Company have commenced trading on SIX Swiss Exchange on 15 May 2018. The total placement volume, excluding the Greenshoe Option, amounts to CHF 155 million which will primarily be used to fund the continued development of Polyphor’s lead product candidate murepavadin towards regulatory approval and further progress the development of balixafortide.

VISCHER AG is acting as Swiss legal counsel to the issuer with Matthias Staehelin (Partner, Corporate) as team leader, Benedict Christ (Partner, Corporate), Angelo Imperiale (Associate, Corporate), Luzius Zumstein (Associate, Corporate), Nadia Tarolli (Partner, Tax) and Adrian Briner (Associate, Tax).